The study evaluating the effect of empagliflozin and  dapagliflozin on miR-133a expression and oxidative stress  in the rat heart induced by streptozotocin/nicotinamide

Ayşe Nur Hazar-yavuz; Elif Beyzanur Polat; Hani Alsaadoni; Hanife Şerife Aktaş; Kübra Elçioğlu

Makale detayları

The study evaluating the effect of empagliflozin and dapagliflozin on miR-133a expression and oxidative stress in the rat heart induced by streptozotocin/nicotinamide

Yazarlar:

Ayşe Nur Hazar-yavuz | Elif Beyzanur Polat | Hani Alsaadoni | Hanife Şerife Aktaş | Kübra Elçioğlu

Yayıncı:

Marmara University

Ana Başlıklar:

Basic Pharmacology

Dergi:

Journal of Research in Pharmacy Vol.28 Issue 6, pp.1892-1900

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001334763

pISSN:

2630-6344

Anahtar kelimeler:

Özet:

 Empagliflozin and dapagliflozin exert their effects by inhibiting sodium glucose cotransporter 2 SGLT2, which inhibits glucose absorption from renal tubules. This class of drugs has also been demonstrated in studies to be protective against cardiovascular complications associated with type 2 diabetes mellitus T2DM. Even in cases without T2DM, they have clinical utility due to their cardioprotective effects. The effects of empagliflozin and dapagliflozin on cardiovascular disorders remain incompletely understood. MicroRNAs miRNAs represent a class of small, non-coding RNA molecules that have been implicated in the pathogenesis of cardiovascular damage. miRNA expressions increase or decrease due to hyperglycemia and oxidative stress that occur in T2DM. This study intended to explore the SGLT2 inhibitor effects on miR-133a expressions in diabetic heart tissue by establishing a streptozotocin STZnicotinamide NA-induced diabetic rat model. Also, antioxidant activities were investigated in the heart and aorta tissue. Male-female Sprague-Dawley rats were injected with NA 100 mgkg and STZ 55 mgkg intraperitoneally i.p. respectively. One week after induction T2DM, treatments were carried out for four weeks. At the and of the treatment, the heart and thoracic aortic tissues of rats were removed. In the heart tissue glutathione GSH, lipid peroxides LPO, and myeloperoxidase MPO levels, and in the aorta tissue GSH and LPO levels were determined by fluorences method. miR-133a expression changes were assessed in the heart tissue by RT-PCR analyses. According to our results, dapagliflozin showed an antioxidant effect by increasing GSH levels in the heart p0.01 and aorta tissue more than empagliflozin. miR-133a expressions increased in the T2DM group and decreased in the EMPA p0.05 and DAPA groups p0.01. Studies on miR-133a expressions in different diabetes models are needed.

 Empagliflozin and dapagliflozin exert their effects by inhibiting sodium glucose cotransporter 2 SGLT2, which inhibits glucose absorption from renal tubules. This class of drugs has also been demonstrated in studies to be protective against cardiovascular complications associated with type 2 diabetes mellitus T2DM. Even in cases without T2DM, they have clinical utility due to their cardioprotective effects. The effects of empagliflozin and dapagliflozin on cardiovascular disorders remain incompletely understood. MicroRNAs miRNAs represent a class of small, non-coding RNA molecules that have been implicated in the pathogenesis of cardiovascular damage. miRNA expressions increase or decrease due to hyperglycemia and oxidative stress that occur in T2DM. This study intended to explore the SGLT2 inhibitor effects on miR-133a expressions in diabetic heart tissue by establishing a streptozotocin STZnicotinamide NA-induced diabetic rat model. Also, antioxidant activities were investigated in the heart and aorta tissue. Male-female Sprague-Dawley rats were injected with NA 100 mgkg and STZ 55 mgkg intraperitoneally i.p. respectively. One week after induction T2DM, treatments were carried out for four weeks. At the and of the treatment, the heart and thoracic aortic tissues of rats were removed. In the heart tissue glutathione GSH, lipid peroxides LPO, and myeloperoxidase MPO levels, and in the aorta tissue GSH and LPO levels were determined by fluorences method. miR-133a expression changes were assessed in the heart tissue by RT-PCR analyses. According to our results, dapagliflozin showed an antioxidant effect by increasing GSH levels in the heart p0.01 and aorta tissue more than empagliflozin. miR-133a expressions increased in the T2DM group and decreased in the EMPA p0.05 and DAPA groups p0.01. Studies on miR-133a expressions in different diabetes models are needed.

 Empagliflozin and dapagliflozin exert their effects by inhibiting sodium glucose cotransporter 2 SGLT2, which inhibits glucose absorption from renal tubules. This class of drugs has also been demonstrated in studies to be protective against cardiovascular complications associated with type 2 diabetes mellitus T2DM. Even in cases without T2DM, they have clinical utility due to their cardioprotective effects. The effects of empagliflozin and dapagliflozin on cardiovascular disorders remain incompletely understood. MicroRNAs miRNAs represent a class of small, non-coding RNA molecules that have been implicated in the pathogenesis of cardiovascular damage. miRNA expressions increase or decrease due to hyperglycemia and oxidative stress that occur in T2DM. This study intended to explore the SGLT2 inhibitor effects on miR-133a expressions in diabetic heart tissue by establishing a streptozotocin STZnicotinamide NA-induced diabetic rat model. Also, antioxidant activities were investigated in the heart and aorta tissue. Male-female Sprague-Dawley rats were injected with NA 100 mgkg and STZ 55 mgkg intraperitoneally i.p. respectively. One week after induction T2DM, treatments were carried out for four weeks. At the and of the treatment, the heart and thoracic aortic tissues of rats were removed. In the heart tissue glutathione GSH, lipid peroxides LPO, and myeloperoxidase MPO levels, and in the aorta tissue GSH and LPO levels were determined by fluorences method. miR-133a expression changes were assessed in the heart tissue by RT-PCR analyses. According to our results, dapagliflozin showed an antioxidant effect by increasing GSH levels in the heart p0.01 and aorta tissue more than empagliflozin. miR-133a expressions increased in the T2DM group and decreased in the EMPA p0.05 and DAPA groups p0.01. Studies on miR-133a expressions in different diabetes models are needed.

 Empagliflozin and dapagliflozin exert their effects by inhibiting sodium glucose cotransporter 2 SGLT2, which inhibits glucose absorption from renal tubules. This class of drugs has also been demonstrated in studies to be protective against cardiovascular complications associated with type 2 diabetes mellitus T2DM. Even in cases without T2DM, they have clinical utility due to their cardioprotective effects. The effects of empagliflozin and dapagliflozin on cardiovascular disorders remain incompletely understood. MicroRNAs miRNAs represent a class of small, non-coding RNA molecules that have been implicated in the pathogenesis of cardiovascular damage. miRNA expressions increase or decrease due to hyperglycemia and oxidative stress that occur in T2DM. This study intended to explore the SGLT2 inhibitor effects on miR-133a expressions in diabetic heart tissue by establishing a streptozotocin STZnicotinamide NA-induced diabetic rat model. Also, antioxidant activities were investigated in the heart and aorta tissue. Male-female Sprague-Dawley rats were injected with NA 100 mgkg and STZ 55 mgkg intraperitoneally i.p. respectively. One week after induction T2DM, treatments were carried out for four weeks. At the and of the treatment, the heart and thoracic aortic tissues of rats were removed. In the heart tissue glutathione GSH, lipid peroxides LPO, and myeloperoxidase MPO levels, and in the aorta tissue GSH and LPO levels were determined by fluorences method. miR-133a expression changes were assessed in the heart tissue by RT-PCR analyses. According to our results, dapagliflozin showed an antioxidant effect by increasing GSH levels in the heart p0.01 and aorta tissue more than empagliflozin. miR-133a expressions increased in the T2DM group and decreased in the EMPA p0.05 and DAPA groups p0.01. Studies on miR-133a expressions in different diabetes models are needed.

Makale detayları

The study evaluating the effect of empagliflozin and dapagliflozin on miR-133a expression and oxidative stress in the rat heart induced by streptozotocin/nicotinamide

Yazarlar:

Ayşe Nur Hazar-yavuz | Elif Beyzanur Polat | Hani Alsaadoni | Hanife Şerife Aktaş | Kübra Elçioğlu

Yayıncı:

Marmara University

Ana Başlıklar:

Basic Pharmacology

Dergi:

Journal of Research in Pharmacy Vol.28 Issue 6, pp.1892-1900

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001334763

pISSN:

2630-6344

Type 2 Diabetes Mellitus

miR-133a

oxidative stress

cardiovascular complications

rat

Sayı

Makale detayları

The study evaluating the effect of empagliflozin and dapagliflozin on miR-133a expression and oxidative stress in the rat heart induced by streptozotocin/nicotinamide

Yazarlar: Ayşe Nur Hazar-yavuz | Elif Beyzanur Polat | Hani Alsaadoni | Hanife Şerife Aktaş | Kübra Elçioğlu

Yayıncı: Marmara University

Ana Başlıklar: Basic Pharmacology

Dergi: Journal of Research in Pharmacy Vol.28 Issue 6, pp.1892-1900

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001334763

pISSN: 2630-6344

Type 2 Diabetes Mellitus

miR-133a

oxidative stress

cardiovascular complications

rat

Sayı

Yazarlar:

Ayşe Nur Hazar-yavuz | Elif Beyzanur Polat | Hani Alsaadoni | Hanife Şerife Aktaş | Kübra Elçioğlu

Yayıncı:

Marmara University

Ana Başlıklar:

Basic Pharmacology

Dergi:

Journal of Research in Pharmacy Vol.28 Issue 6, pp.1892-1900

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001334763

pISSN:

2630-6344